Endocrine system recommendations
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on firstname.lastname@example.org
|FreeStyle Libre 2 and Dexcom One||NTAG CGM position statement - November 2022_FINAL - amended 21.2.23||Recommended for use as per NICE guidance||15/11/2022|
|Insulin Glargine (Toujeo®)||Recommendation||Recommended as an option||24/11/2015|
|Insulin Glargine Biosimilar(Abasaglar®)||Recommendation||Recommended first line||24/11/2015|
|i-Port Advance® for use in children and adults with diabetes||Recommendation||Recommended as an option||07/06/2022|
|OmniPod® CSII system for diabetes||Recommendation||Recommended as an option||02/06/2015|
|Semaglutide (oral) for type 2 diabetes||Recommendation||Recommended as an option for intensification of treatment, if use of GLP1RA is clinically appropriate, and if an oral option is preferred.||01/09/2020|
|Teriparatide Biosimilar||Recommendation||Recommend for the treatment of osteoporosis in postmenopausal women as per NICE TA161||08/12/2020|
|Teriparatide for atypical bisphosphonate induced fractures||Recommendation||Not recommended||23/02/2021|
|North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i)||NENC regional SGLT2 top tips v1.2 - NTAG approved March 2023||Approved by NTAG||21/03/2023|